Innovative Targeting Solutions Initiates Research Collaboration

BURNABY, BC, Jan. 19, 2012 /CNW/ - Innovative Targeting Solutions Inc. (ITS), the developer of the next generation fully human antibody technology (HuTARG), today announced the initiation of a research collaboration with Amgen Inc. (Thousand Oaks, CA). The agreement will allow Amgen to assess ITS's HuTARG technology for a broader potential collaboration in the future.

About Innovative Targeting Solutions Inc.
Founded in 2008, Innovative Targeting Solutions Inc. is a privately-held company that has developed a next generation platform for the generation of fully human antibody therapeutics using its proprietary HuTARG technology. The HuTARG technology is a fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information, visit www.innovativetargeting.com

SOURCE Innovative Targeting Solutions Inc

For further information:

For more information, visit www.innovativetargeting.com

Profil de l'entreprise

Innovative Targeting Solutions Inc

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.